Methotrexate Accord

Methotrexate, the active ingredient in Methotrexate Accord, is an antimetabolite (folate antagonist) presented as an oral tablet for oral use. It is employed to treat autoimmune disorders and certain cancers in adult patients, including rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia and non‑Hodgkin lymphoma.

GNH USA supplies Methotrexate Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery to oncology centres, rheumatology units and transplant facilities across Europe, Asia and the Americas.

Methotrexate is used in several disease categories, primarily autoimmune disorders and malignancies, where it modulates cell proliferation. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: decreases skin cell turnover, improving plaque severity. - Acute lymphoblastic leukemia: interferes with leukemic cell replication, contributing to remission. - Non‑Hodgkin lymphoma: impairs lymphoma cell growth as part of combination therapy. - Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Stomatitis or mouth ulcers - Elevated liver enzymes

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis - Pulmonary toxicity (interstitial pneumonitis) - Significant bone marrow failure (aplastic anemia)

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on safety measures. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Assess blood counts: regular CBC to detect bone marrow suppression. - Evaluate renal function: adjust dose if creatinine clearance is reduced. - Avoid use in pregnancy: teratogenic risk mandates strict contraception. - Counsel on folic acid supplementation: may reduce mucosal toxicity. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Methotrexate has several drug interactions that may require avoidance or close monitoring.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise serum levels. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely): - Penicillins (high‑dose): can reduce renal clearance of methotrexate. - Live vaccines: risk of infection due to immunosuppression. - Alcohol: may exacerbate hepatotoxicity.